STOCK TITAN

MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will present at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on demand starting March 9, 2021, at 7:00 am (ET). Interested viewers can access the webcast link from the Events & Presentations section of MannKind's website. The replay will be available for 14 days after the live event. MannKind focuses on inhaled therapeutic products, including the FDA-approved Afrezza®, an ultra-rapid-acting mealtime insulin available by prescription in the U.S. and Brazil.

Positive
  • None.
Negative
  • None.

WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will present at the H.C. Wainwright Global Life Sciences Conference which will be available on demand starting on March 9, 2021 at 7:00 am (ET). Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.  Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA. MannKind is headquartered in Westlake Village, California, and has a state-of-the-art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
818-661-5000
ir@mannkindcorp.com


FAQ

When will MannKind's CEO present at the H.C. Wainwright Conference?

MannKind's CEO will present at the H.C. Wainwright Global Life Sciences Conference starting on March 9, 2021, at 7:00 am (ET).

Where can I access the MannKind webcast for the H.C. Wainwright Conference?

You can access the MannKind webcast link from the Events & Presentations section of their website.

How long will the MannKind presentation be available for replay?

The MannKind presentation will be available for replay for 14 days following the live event.

What product does MannKind commercialize?

MannKind commercializes Afrezza® (insulin human) Inhalation Powder, the only inhaled ultra-rapid-acting mealtime insulin in the U.S.

In which countries is Afrezza available?

Afrezza is available by prescription in the United States and Brazil.

Mannkind Corporation

NASDAQ:MNKD

MNKD Rankings

MNKD Latest News

MNKD Stock Data

1.92B
270.76M
1.83%
56.64%
15.54%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DANBURY